The two-day Peptide Drug Summit begins today in Munich, gathering developers to tackle the stability and delivery hurdles that still limit many peptide therapeutics.
The Peptide Drug Summit runs October 14 to 15, 2026 in Munich, Germany, bringing together pharmaceutical developers, contract manufacturers and academic groups working on peptide-based medicines. The program is built around three persistent technical challenges: delivery, molecular stability and bioavailability.
The timing reflects a year in which oral peptides moved from aspiration to approved products. Macrocyclic and cyclic designs that survive the digestive tract have now reached the market in both dermatology and cardiology, and much of the industry conversation has shifted to how broadly those approaches can be applied.
The event is promoted locally by Bavaria's BioM life-sciences network. Sessions are expected to cover formulation, half-life extension and manufacturing scale-up as demand for peptide APIs continues to grow alongside the obesity drug boom.
Source: BioM — Peptide Drug Summit 2026
Share this article
The Peptide Wizard
High-quality research peptides for lab use. Third-party tested with certificate of analysis available on every product.
Visit The Peptide WizardSponsored content. ThePBrief receives compensation. For research purposes only.